ST人福 (600079.SH) Latest Company News

Sep 3, 2026, 08:37 UTC
ST Renfu's controlled subsidiary Yichang Renfu announced that its drug RFUS-949 tablets have entered Phase II clinical trials for the treatment of acute and chronic pain.
Source:
- finance.sina.cn
Aug 31, 2026, 07:41 UTC
Humanwell Healthcare's subsidiary Yichang Humanwell Pharmaceutical received acceptance of its marketing authorization application for pregabalin extended-release tablets from China's National Medical Products Administration.
Source:
- finance.sina.cn
Aug 25, 2026, 09:10 UTC
ST Renfu announced its first-half 2026 results: revenue of 12.061 billion yuan, net profit attributable to shareholders up 15.15% year-on-year.
Source:
- finance.sina.cn
Jul 24, 2026, 07:50 UTC
ST Renfu's wholly-owned subsidiary Wuhan Puke obtained a drug registration certificate for Vinorelbine Tartrate Soft Capsules, valid until July 20, 2031.
Source:
- finance.sina.cn
Jul 10, 2026, 08:40 UTC
ST Renfu's subsidiary Renfu Puke Pharmaceutical (Wuhan) received FDA approval for Nintedanib Capsules.
Source:
- finance.sina.cn
Jul 9, 2026, 07:44 UTC
ST Renfu's wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. registered the Phase II clinical trial of HW211026 ointment on the National Medical Products Administration's drug clinical trial registration and information publicity platform.
Source:
- finance.sina.cn
Jul 6, 2026, 07:45 UTC
ST Renfu's controlled subsidiary Yichang Renfu received drug clinical trial approval from the National Medical Products Administration for hydromorphone hydrochloride tablets.
Source:
- finance.sina.cn
- finance.sina.cn

600079.SH

ST Renfu's controlled subsidiary Yichang Renfu announced that its drug RFUS-949 tablets have entered Phase II clinical trials for the treatment of acute and chronic pain.

Humanwell Healthcare's subsidiary Yichang Humanwell Pharmaceutical received acceptance of its marketing authorization application for pregabalin extended-release tablets from China's National Medical Products Administration.

ST Renfu announced its first-half 2026 results: revenue of 12.061 billion yuan, net profit attributable to shareholders up 15.15% year-on-year.

ST Renfu's wholly-owned subsidiary Wuhan Puke obtained a drug registration certificate for Vinorelbine Tartrate Soft Capsules, valid until July 20, 2031.

ST Renfu's subsidiary Renfu Puke Pharmaceutical (Wuhan) received FDA approval for Nintedanib Capsules.

ST Renfu's wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. registered the Phase II clinical trial of HW211026 ointment on the National Medical Products Administration's drug clinical trial registration and information publicity platform.

ST Renfu's controlled subsidiary Yichang Renfu received drug clinical trial approval from the National Medical Products Administration for hydromorphone hydrochloride tablets.